Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys
暂无分享,去创建一个
Bette Korber | Michael S. Seaman | James J. Szinger | Will Fischer | B. Korber | W. Fischer | K. Mansfield | M. Muldoon | Nathaniel L. Simmons | D. Barouch | M. Seaman | P. Abbink | James Szinger | Dan H. Barouch | Mark Muldoon | Kara L. O’Brien | Sharon L. King | Ying-Hua Sun | Peter Abbink | Lori F. Maxfield | A. Carville | Kara L. O'Brien | Ying-Hua Sun | Annalena La Porte | Ambryice M. Riggs | Diana M. Lynch | Sarah L. Clark | Katherine Backus | James R. Perry | Angela Carville | Keith G. Mansfield | A. La Porte | J. Perry | Sarah L Clark | L. Maxfield | N. Simmons | Katherine Backus
[1] Peter B Gilbert,et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. , 2006, Vaccine.
[2] D. Montefiori,et al. Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.
[3] David C Montefiori,et al. Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants , 2005, Nature Immunology.
[4] D. Montefiori,et al. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.
[5] J. Kublin,et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] J. Safrit,et al. Depletion of CD8+ Cells in Sooty Mangabey Monkeys Naturally Infected with Simian Immunodeficiency Virus Reveals Limited Role for Immune Control of Virus Replication in a Natural Host Species1 , 2007, The Journal of Immunology.
[7] Alan S. Perelson,et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection , 2009, The Journal of experimental medicine.
[8] James Theiler,et al. Web-based design and evaluation of T-cell vaccine candidates , 2008, Bioinform..
[9] K. Mansfield,et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.
[10] B. Korber,et al. Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination , 2008, Journal of Virology.
[11] K. Mansfield,et al. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D , 2007, Journal of Virology.
[12] Devan V Mehrotra,et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.
[13] Donald K Carter,et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.
[14] B. Korber,et al. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys , 2008, Proceedings of the National Academy of Sciences.
[15] James Theiler,et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.
[16] D. Douek,et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts , 2009, Nature Medicine.
[17] David Heckerman,et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.
[18] Norman L. Letvin,et al. T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces , 2009, Journal of Virology.
[19] D. Barouch,et al. Challenges in the development of an HIV-1 vaccine , 2008, Nature.
[20] V. Carey,et al. Mixed-Effects Models in S and S-Plus , 2001 .